DOLOMITE - Safety and effectiveness of DTG use in pregnancy

 

A multi-site observational study to define the safety and effectiveness of Dolutegravir use in HIV positive pregnant women

 

Indication:  HIV positive women receiving DTG (at least 200 starting or on DTG in the first trimester)

 

Phase: IV

 

Countries:  Canada, Europe

 

Status: Actively recruiting

Administrative office: NEAT ID Foundation, 27 Old Gloucester Street, London WC1N 3AX, UK

     e: NEAT-ID@NEAT-ID.org     

w: www.NEAT-ID.org

Registered address: PL 709  Rue Haute 322, 1000 Brussels, Belgium

©NEAT ID 2019